JP6938835B2 - レプチン欠乏状態を治療するためのｃｄ２４タンパク質の使用 - Google Patents

レプチン欠乏状態を治療するためのｃｄ２４タンパク質の使用 Download PDF

Info

Publication number
JP6938835B2
JP6938835B2 JP2018539976A JP2018539976A JP6938835B2 JP 6938835 B2 JP6938835 B2 JP 6938835B2 JP 2018539976 A JP2018539976 A JP 2018539976A JP 2018539976 A JP2018539976 A JP 2018539976A JP 6938835 B2 JP6938835 B2 JP 6938835B2
Authority
JP
Japan
Prior art keywords
hours
protein
seq
minutes
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018539976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506408A (ja
JP2019506408A5 (enExample
Inventor
リウ，　ヤン
ヤン リウ，
パン ジェン，
パン ジェン，
マーティン デベンポート，
マーティン デベンポート，
Original Assignee
オンコイミューン， インコーポレイテッド
オンコイミューン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコイミューン， インコーポレイテッド, オンコイミューン， インコーポレイテッド filed Critical オンコイミューン， インコーポレイテッド
Publication of JP2019506408A publication Critical patent/JP2019506408A/ja
Publication of JP2019506408A5 publication Critical patent/JP2019506408A5/ja
Application granted granted Critical
Publication of JP6938835B2 publication Critical patent/JP6938835B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018539976A 2016-02-02 2017-02-02 レプチン欠乏状態を治療するためのｃｄ２４タンパク質の使用 Expired - Fee Related JP6938835B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290202P 2016-02-02 2016-02-02
US62/290,202 2016-02-02
PCT/US2017/016120 WO2017136492A1 (en) 2016-02-02 2017-02-02 Use of cd24 proteins for treating leptin-deficient conditions

Publications (3)

Publication Number Publication Date
JP2019506408A JP2019506408A (ja) 2019-03-07
JP2019506408A5 JP2019506408A5 (enExample) 2020-03-12
JP6938835B2 true JP6938835B2 (ja) 2021-09-22

Family

ID=59500202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018539976A Expired - Fee Related JP6938835B2 (ja) 2016-02-02 2017-02-02 レプチン欠乏状態を治療するためのｃｄ２４タンパク質の使用

Country Status (8)

Country Link
US (2) US10799558B2 (enExample)
EP (1) EP3411062B1 (enExample)
JP (1) JP6938835B2 (enExample)
KR (1) KR20180120145A (enExample)
CN (1) CN109069583B (enExample)
CA (1) CA3012466A1 (enExample)
SG (1) SG11201806338SA (enExample)
WO (1) WO2017136492A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630158B1 (en) * 2017-05-22 2022-07-13 Oncoimmune, Inc. Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
US20210046154A1 (en) * 2018-03-05 2021-02-18 Oncoimmune, Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
TW202015753A (zh) * 2018-06-04 2020-05-01 美商昂科免疫公司 以cd24預防及治療移植物抗宿主病及黏膜炎之方法
WO2020163529A1 (en) 2019-02-06 2020-08-13 Oncoimmune, Inc. Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis
US20220000974A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
JP2007504842A (ja) * 2003-05-29 2007-03-08 ミレニアム ファーマシューティカルズ， インコーポレイテッド 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
ES2826445T3 (es) * 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
CA2851602C (en) 2011-08-30 2020-07-14 Academisch Medisch Centrum Method for preventing and/or treating insulin resistance
WO2014071379A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Dosing and administration of oligonucleotide cancer therapies

Also Published As

Publication number Publication date
JP2019506408A (ja) 2019-03-07
US20190038716A1 (en) 2019-02-07
CN109069583A (zh) 2018-12-21
US20210162006A1 (en) 2021-06-03
WO2017136492A1 (en) 2017-08-10
CA3012466A1 (en) 2017-08-10
CN109069583B (zh) 2021-09-21
KR20180120145A (ko) 2018-11-05
EP3411062A4 (en) 2019-09-25
EP3411062A1 (en) 2018-12-12
SG11201806338SA (en) 2018-08-30
US10799558B2 (en) 2020-10-13
EP3411062B1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
EP3292144B1 (en) Use of cd24 for lowering low-density lipoprotein cholesterol levels
US20210162006A1 (en) Use of CD24 Proteins for Treating Leptin-Deficient Conditions
KR102887037B1 (ko) 호중구 질환을 치료하는 방법
TW201709927A (zh) 使用ＡＣＴＲＩＩ配位體捕捉以治療β－地中海型貧血
KR20160067984A (ko) Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
JP2021511362A (ja) 組成物及び使用方法
US20230414717A1 (en) Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
TW202434624A (zh) 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法
AU2013344973B2 (en) Compositions and methods for the treatment of ectodermal dysplasia
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법
KR20230145120A (ko) 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법
HK40002090B (en) Use of cd24 proteins for treating leptin-deficient conditions
HK40002090A (en) Use of cd24 proteins for treating leptin-deficient conditions
WO2025120567A1 (en) Method of treatment of asthma
EP3921339A2 (en) Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes
Class et al. Patent application title: BChE ALBUMIN FUSIONS FOR THE TREATMENT OF COCAINE ABUSE Inventors: Liora Sklair-Tavron (Zichron Yaakov, IL) Moti Rosenstock (Menashe, IL) Liron Shemesh-Darvish (Ramat-Gan, IL) Hussein Hallak (Jerusalem, IL) Victor Piryatinsky (Netanya, IL) Viktor Roschke (Bethesda, MD, US) Viktor Roschke (Bethesda, MD, US) David Lafleur (Washington, DC, US) David Lafleur (Washington, DC, US) Assignees: Teva Pharmaceutical Industries Ltd.
HK1213804B (en) Follistatin in treating duchenne muscular dystrophy

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191028

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210812

R150 Certificate of patent or registration of utility model

Ref document number: 6938835

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees